University of Calgary
UofC Navigation

Braden Manns

Braden Manns

Svare Professor in Health Economics

Interim Scientific Director

Alberta Health Services Kidney Strategic Clinical Network University of Calgary


Braden Manns is the Svare Professor in Health Economics and a Nephrologist at the University of Calgary in the Departments of Medicine and Community Health Sciences and an Alberta Innovates – Health Solutions Health Scholar. The mission of the Svare Chair is to develop a world-class Health Economics research and academic program that focuses on evaluating the clinical and economic impact of health care technologies and health care policies of relevance to health care policy makers. He has expertise in Applied Health Economics and clinical research in Nephrology and is co-PI for an inter-disciplinary team grant investigating chronic disease ( ).

Dr. Manns current research interests include examining the implications of patient-borne costs on care and outcomes in chronic disease, examining the cost effectiveness of strategies and health care policies for managing patients with chronic disease, and assessing the adequacy of care for Albertans with diabetes, among other projects. He has experience in pharmaceutical priority setting, having served on provincial and national committees for drug evaluation, including a term as Chair of Canadian Expert Drug Advisory Committee from 2006-2008. Dr. Manns is the President of the Canadian Society of Nephrology and principal investigator of a Canadian kidney disease knowledge translation network, guiding health policy for patients with kidney disease ( ). Dr. Manns teaches a graduate course in economic evaluation and supervises graduate students at all levels of training.

Key Publications

  • Tang KL, Ghali WA, Manns BJ.  Addressing cost-related barriers to prescription drug use in Canada.  CMAJ. 2014 Mar 4; 186(4): 276–280.
  • Campbell DJ, King-Shier K, Hemmelgarn BR, Sanmartin C, Ronksley PE, Weaver RG, Tonelli M, Hennessy D, Manns BJ. Self-reported financial barriers to care among patients with cardiovascular-related chronic conditions. Health Rep. 2014 May 21;25(5):3-12.
  • Manns B, Hemmelgarn B, Tonelli M, Chiasson C, Au F, Dong J, Klarenbach S.  Population based screening for chronic kidney disease: cost effectiveness study.  BMJ 2010, Nov 8;341:c5869
  • Heitman S, Hilsden R, Au F, Dowden S, Manns B. Colorectal cancer screening for average risk North Americans: an economic evaluation. PLOS Med. 2010: 23;7(11): e1000370
  • Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns B.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.  JAMA. 2009 Oct 7;302(13):1437-43. 
  • Manns, B, Lee H, Doig CJ, Johnson D, Donaldson, C. An Economic Evaluation of Activated Protein C Treatment in Severe Sepsis. N Engl J Med, 2002; 347: 993-1000.